AR SB840

Creates the "Abortion-Inducing Drugs Safety Act" requiring abortion-inducing drugs to be administered according to FDA-tested and FDA-approved protocols as outlined in drug labels, specifically limiting mifepristone use to within 49 days of last menstrual period with three office visits and physician supervision.

Prohibits off-label use of mifepristone and other abortion-inducing drugs, requiring physicians to examine patients and document gestational age and intrauterine pregnancy location before administration.

Mandates physicians prescribing abortion-inducing drugs maintain signed contracts with backup physicians for emergency care at designated hospitals with active admitting and gynecological/surgical privileges.

Requires physicians to report any adverse events to the FDA Medwatch system and Arkansas State Medical Board within 3 days, with reports compiled as public records while protecting patient identity.

Establishes civil liability for violations including malpractice actions, professional disciplinary action, and wrongful death recovery; imposes criminal penalties for purposeful, knowing, or reckless violations; and requires Department of Health inspections of abortion facilities at least every 6 months.